Idelalisib induced drug toxicity presenting as drug induced pneumonitis: a case report

Authors

  • Sameer Verma Department of Pulmonary, Critical Care and Sleep Medicine, Northwell Health, New Hyde Park, NY, USA
  • Dhwani Pandya Department of Medicine, Staten Island University Hospital, Staten Island, NY 10305, USA
  • Sameer Khanijo Department of Pulmonary, Critical Care and Sleep Medicine, Northwell Health, New Hyde Park, NY, USA
  • Michael Esposito Department of Pulmonary, Critical Care and Sleep Medicine, Northwell Health, New Hyde Park, NY, USA
  • Arunabh Talwar Department of Pulmonary, Critical Care and Sleep Medicine, Northwell Health, New Hyde Park, NY, USA

DOI:

https://doi.org/10.18203/2349-3933.ijam20211062

Keywords:

Idelalisib, Chornic lymphocytic leukemia, Drug induced interstitial lung diseases, Phosphatidylinositol 3 kinase inhibitor, Steroids

Abstract

Idelalisib is a novel treatment option for patients with chronic lymphocytic leukemia. A rare, but, fatal complication of using Idelalsib is drug induced pneumonitis. This article presents a case of Idelalsib induced pneumonitis in a patient with chronic lymphocytic leukemia along with a brief discussion of management plan.

Author Biography

Michael Esposito, Department of Pulmonary, Critical Care and Sleep Medicine, Northwell Health, New Hyde Park, NY, USA

Department of Pathology, Northwell Health, New Hyde Park, NY 11040

References

Travis WD, Costabel U, Hansell DM. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733-48.

Erasmus JJ, McAdams HP, Rossi SE. Drug-induced lung injury. Semin Roentgenol 2002;37:72-81.

Ripley BA KT, Gill RR. Deciphering drug-induced interstitial lung disease: A mechanistic approach Appl Radiol. 2016;45:9-18.

Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012;13:39.

Cleverley JR, Screaton NJ, Hiorns MP, Flint JD, Muller NL. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol. 2002;57:292-9.

Skeoch S, Weatherley N, Swift AJ. Drug-Induced Interstitial Lung Disease: A Systematic Review. J Clin Med. 2018;7.

Pietra GG. Pathologic mechanisms of drug-induced lung disorders. J Thorac Imaging. 1991;6:1-7.

Schwaiblmair M, Behr W, Haeckel T, Markl B, Foerg W, Berghaus T. Drug induced interstitial lung disease. Open Respir Med J. 2012;6:63-74.

Simpson AB, Paul J, Graham J, Kaye SB. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br J Cancer. 1998;78:1061-6.

Mendez JL, Nadrous HF, Hartman TE, Ryu JH. Chronic nitrofurantoin-induced lung disease. Mayo Clin Proc 2005;80:1298-302.

Reinert T BC, Nunes FAP, Scheliga AAdS. Bleomycin-Induced Lung Injury. Journal of Cancer Research. 2013;2013:9.

Crimi E, Sica V, Williams-Ignarro S. The role of oxidative stress in adult critical care. Free Radic Biol Med. 2006;40:398-406.

Miyakoshi S, Kami M, Yuji K. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood. 2006;107:3492-4.

Ohri A, Arena FP. Severe pulmonary complications in African-American patient after bortezomib therapy. Am J Ther. 2006;13:553-5.

Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum. 2006;54:1435-9.

Miwa Y, Isozaki T, Wakabayashi K. Tacrolimus-induced lung injury in a rheumatoid arthritis patient with interstitial pneumonitis. Mod Rheumatol. 2008;18:208-11.

Sleijfer S, van der Mark TW, Schraffordt Koops H, Mulder NH. Enhanced effects of bleomycin on pulmonary function disturbances in patients with decreased renal function due to cisplatin. Eur J Cancer. 1996;32A:550-2.

Oya N, Sasai K, Tachiiri S. Influence of radiation dose rate and lung dose on interstitial pneumonitis after fractionated total body irradiation: acute parotitis may predict interstitial pneumonitis. Int J Hematol. 2006;83:86-91.

Yang Q, Modi P, Newcomb T, Queva C, Gandhi V. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma. Clin Cancer Res. 2015;21:1537-42.

Fruman DA, Cantley LC. Idelalisib--a PI3Kdelta inhibitor for B-cell cancers. N Engl J Med. 2014;370:1061-2.

Coutre SE, Barrientos JC, Brown JR. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56:2779-86.

Drug statistical FDA. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206545lbl.pdf. Accessed 10 August 2020.

Chuzi S, Tavora F, Cruz M. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res 2017;9:207-13.

Vulisha AK, Talwar A, Verma S, Gupta A, Lam L. Nivolumab Induced Toxicity Presenting As Pneumonitis- A Case Report. J Pulm Respir Med 2018;8.

Downloads

Published

2021-03-23

Issue

Vol. 8 No. 4 (2021): April 2021

Section

Case Reports